Claim/exemption information - Registry number 11264

Case number
2020-011576
Claimant name
Ingevity Corporation
Product identifier
INDULIN® SBT
Claim type
Refile
Date of filing
Claim validity status
Valid
Claim validity decision date
Exemption expiry date
Non-compliance(s) identified on SDS and/or label
Yes, Order issued
SDS and/or label compliance review decision date
Claim/exemption status
Expired

Additional information

Date of the order
Order status
Unresolved

List of suggested corrective measures

  • Correct the disclosure of misleading information regarding section 6, “Accidental release measures”.

  • Correct the disclosure of misleading information regarding section 8, “Exposure controls/Personal protection”.

  • Correct the misleading information regarding section 7, “Handling and storage”.

  • Disclose a clear link between all of the applicable confidential business information and the HMIRA registry number.

  • Disclose a statement equivalent to “Wash ... thoroughly after handling” in section 7.

  • Disclose the additional hazard classification of “Specific Target Organ Toxicity — Single Exposure — Category 1 (kidneys, central nervous system)”.

  • Disclose the information elements concerning the additional hazard and precautionary statements.

  • Disclose the necessary protective equipment in section 6, “Accidental release measures”.

  • Disclose the signal word “Danger”.

  • Disclose “Other hazards” on the SDS.

Date modified: